GMED vs. RMD, STE, BAX, HOLX, PODD, TFX, MASI, ITGR, IART, and ATEC
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include ResMed (RMD), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), Masimo (MASI), Integer (ITGR), Integra LifeSciences (IART), and Alphatec (ATEC). These companies are all part of the "health care equipment" industry.
ResMed (NYSE:RMD) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
55.0% of ResMed shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 1.2% of ResMed shares are held by company insiders. Comparatively, 18.5% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ResMed currently has a consensus target price of $202.80, indicating a potential downside of 1.71%. Globus Medical has a consensus target price of $69.40, indicating a potential upside of 3.41%. Given ResMed's higher probable upside, analysts clearly believe Globus Medical is more favorable than ResMed.
In the previous week, Globus Medical had 9 more articles in the media than ResMed. MarketBeat recorded 21 mentions for Globus Medical and 12 mentions for ResMed. ResMed's average media sentiment score of 1.01 beat Globus Medical's score of 0.96 indicating that Globus Medical is being referred to more favorably in the news media.
ResMed has a net margin of 20.91% compared to ResMed's net margin of 3.51%. Globus Medical's return on equity of 24.43% beat ResMed's return on equity.
ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
ResMed has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Globus Medical received 132 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 67.87% of users gave Globus Medical an outperform vote while only 52.93% of users gave ResMed an outperform vote.
Summary
Globus Medical beats ResMed on 9 of the 17 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
